Coronary sinus reducer: a new hope for refractory angina?

Affiliations

¹ Postgraduation School in Radiodiagnostics, University of Milan, 20133 Milan, Italy. Electronic address: caterinab.monti@gmail.com.
² Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.

Comment

Caterina B Monti et al. Lancet. 2024.

. 2024 Apr 20;403(10436):1514-1515.

doi: 10.1016/S0140-6736(24)00474-4. Epub 2024 Apr 8.

¹ Postgraduation School in Radiodiagnostics, University of Milan, 20133 Milan, Italy. Electronic address: caterinab.monti@gmail.com.
² Clinical and Experimental Radiology Unit, Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.

No abstract available

Conflict of interest statement

CBM reports support for attending meetings from Bracco. AP declares no competing interests.

Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
Foley MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, Chotai S, Pathimagaraj RH, Mohsin M, Salih A, Wang D, Dixit P, Davies JR, Keeble TR, Cosgrove C, Spratt JC, O'Kane PD, De Silva R, Hill JM, Nijjer SS, Sen S, Petraco R, Mikhail GW, Khamis R, Kotecha T, Harrell FE, Kellman P, Francis DP, Howard JP, Cole GD, Shun-Shin MJ, Al-Lamee RK. Foley MJ, et al. Lancet. 2024 Apr 20;403(10436):1543-1553. doi: 10.1016/S0140-6736(24)00256-3. Epub 2024 Apr 8. Lancet. 2024. PMID: 38604209 Clinical Trial.